Project 2: Relating ENM Physicochemical Properties to Mechanism-Based Pulmonary T

项目 2:将 ENM 理化特性与基于机制的肺 T 联系起来

基本信息

项目摘要

The importance of developing a predictive toxicity paradigm to assess ENM hazard in the lung Pulmonary toxicity as a result of inhaling engineered nanomaterials (ENM) depends on the unique physicochemical properties that allow these materials to perturb bio-molecules and bio-molecular processes in the lung.{1} We define the nano-bio interface as the interacfion of ENM surfaces, which are shaped by intrinsic material properties as well as the dynamic modificafion of those properties by environmental media, with proteins, DNA, membranes, lipids, cell surfaces, endocytic pathways, intracellular organelles, cytosol, nucleus, biological fluids, fissue and organs.{2} {1}While ENM-based products such as nanocomposites, surface coafings and electronic circuits are unlikely to pose a direct risk to the lung, ENM that are being produced as nanoparticles, agglomerates of nanoparticles or particles comprised of nanostructured materials are more likely to pose a hazard to the lung.^ While it is theorefically possible to subject every new material that is being produced as an unattached particle to rigorous inhalafion toxicity testing in animals, this is logisfically unfeasible at the rates at whicti new ENM are being produced, including cost and animal use considerafions. This limits the number of different material composifions that can be studied in animals as well as the ability to assess all the physicochemical properties that can be engineered into one material, including size, surface area, shape, crystallinity, surface charge, reactive surface groups, dissolufion, state of aggregation or dispersal etc. It is our opinion that knowledge generafion about ENM hazard has to consider additional approaches that complement animal testing.{3} In this proposal, we recommend the implementation of a predictive toxicological paradigm, which is defined as the assessment of in vivo toxic potential of ENM based on in vitro and in silico methods.{3} Predictive toxicology is an essential tool for successful drug development because toxicity is one of the major reasons for product failure in the drug development process. It is essential to identify and exclude new drug candidates with unfavorable safety profiles as early as possible in the development process. Predictive toxicology has recently also being introduced to industrial chemical toxicity. Both the Nafional Toxicology Program as well as the Nafional Research Council (NRC) in the US Nafional Academy of Sciences (NAS) have recommended that toxicological testing in the 21st-century evolve from a predominanfiy observafional science at the level of disease-specific models to predictive science models focused on broad inclusion of target-specific, mechanism-based biological observations.{4-6} It is further recommended that the biological testing be based on robust scientific paradigms that can be used to screen mulfiple toxicants at one fime instead of costly animal experiments looking at a single toxicant at one fime. A report outlining the US Federal Government response to the NRC document was published in 2008 and prompted NIEHS, EPA and the National Institute of Health Chemical Genomics Center to sign an agreement to collaborate on the development and evaluation of a rapid and high volume screening methodologies to: (i) prioritize substances for more comprehensive toxicological tesfing, (ii) identify mechanisms of acfion for further invesfigafion, and (iii) develop predictive models for in vivo biological response monitoring for commercial chemicals with inadequate or nonexistent toxicological data. Although this change in toxicological assessment philosophy has catalyzed a healthy and rigorous debate among toxicologists, regulators and the public, our opinion is that it is fimely to consider an analogous approach for ENM hazard assessment. Importanfiy, we do not recommend doing away with animal experiments but we advocate the use of toxicological or mechanistic injury pathways to establish in vitro property-activity relafionships that can be used for knowledge generafion and logical planning of animal testing. Project 2 will determine whether the property-activity relafionships to be explored by carefully chosen and wellcharacterized compositional and combinatorial ENM libraries can help us understand the material properties leading to pulmonary inflammation, cytotoxicity and fibrosis. Integral to understanding these properties is the ability to develop dosimetry models that consider biological hazard in dose quantifies other than mass.{2}
吸入工程纳米材料(ENM)导致的肺毒性取决于独特的物理化学性质,这些性质允许这些材料干扰肺部的生物分子和生物分子过程。{1}我们将纳米生物界面定义为ENM表面与蛋白质、DNA、膜、脂质、细胞表面、内吞途径、细胞器、胞质溶胶、细胞核、生物液体、裂隙和器官的相互作用,ENM表面由内在材料性质以及环境介质对这些性质的动态修饰形成。{2}{1}虽然基于ENM的产品(如纳米复合材料、表面涂层和电子电路)不太可能对肺部造成直接风险,但以纳米颗粒、纳米颗粒团聚体或由纳米结构材料组成的颗粒形式生产的ENM更有可能对肺部造成危害。虽然理论上有可能使作为独立颗粒生产的每种新材料在动物中进行严格的吸入毒性测试,但在生产新ENM的速度下,这在逻辑上是不可行的,包括成本和动物使用方面。 这限制了可以在动物中研究的不同材料组合物的数量以及评估可以被设计成一种材料的所有物理化学性质的能力,所述物理化学性质包括尺寸、表面积、形状、结晶度、表面电荷、反应性表面基团、溶解度和溶解度。我们认为,关于ENM危害的知识生成必须考虑补充的其他方法,动物实验{3} 在本提案中,我们建议实施预测毒理学范式,其定义为基于体外和计算机模拟方法评估ENM的体内毒性潜力。{3}预测毒理学是成功药物开发的重要工具,因为毒性是产品毒性的主要原因之一。 药物开发过程中的失败。在开发过程中尽早识别和排除具有不利安全性特征的候选新药至关重要。预测毒理学最近也被引入工业化学品毒性。美国国家毒理学计划和美国国家科学院(NAS)的国家研究理事会(NRC)都建议,21世纪的毒理学测试从疾病特异性模型水平的主要观察科学发展为预测科学模型,重点是广泛纳入目标特异性,基于机制的生物学观察。{4-6}还建议生物试验应基于可靠的科学范例,可用于一次性筛选多种毒物,而不是一次性研究单一毒物的昂贵动物实验。2008年发表了一份报告,概述了美国联邦政府对NRC文件的回应,并促使NIEHS、EPA和国家卫生研究所化学基因组学中心签署了一项协议,合作开发和评估快速和高容量筛选方法,以:(i)确定物质的优先次序,以便进行更全面的毒理学测试,(ii)确定acfion的机制,以便进一步研究,和(iii)开发预测模型,用于对毒理学数据不足或不存在的商业化学品进行体内生物反应监测。 尽管毒理学评估理念的这一变化在毒理学家、监管机构和公众之间引发了一场健康而严格的辩论,但我们的观点是,考虑采用类似的方法进行ENM危害评估是明智的。重要的是,我们不建议取消动物实验,但我们提倡使用毒理学或机械损伤途径来建立体外性质-活性相关性,可用于动物试验的知识生成和逻辑规划。 项目2将确定通过精心选择和良好表征的组成和组合ENM库探索的性质-活性相关性是否可以帮助我们理解导致肺部炎症,细胞毒性和纤维化的材料性质。理解这些特性的必要条件是能够开发剂量测定模型,该模型以剂量而非质量的形式考虑生物危害。{1}、{2}

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Andre Elias Nel其他文献

Andre Elias Nel的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Andre Elias Nel', 18)}}的其他基金

Use of a Nano-Enabled Platform for Pancreatic Cancer Immunotherapy
使用纳米平台进行胰腺癌免疫治疗
  • 批准号:
    10187533
  • 财政年份:
    2020
  • 资助金额:
    $ 37.25万
  • 项目类别:
Use of a Nano-Enabled Platform for Pancreatic Cancer Immunotherapy
使用纳米平台进行胰腺癌免疫治疗
  • 批准号:
    10058189
  • 财政年份:
    2020
  • 资助金额:
    $ 37.25万
  • 项目类别:
Use of a Nano-Enabled Platform for Pancreatic Cancer Immunotherapy
使用纳米平台进行胰腺癌免疫治疗
  • 批准号:
    10417161
  • 财政年份:
    2020
  • 资助金额:
    $ 37.25万
  • 项目类别:
Use of a Nano-Enabled Platform for Pancreatic Cancer Immunotherapy
使用纳米平台进行胰腺癌免疫治疗
  • 批准号:
    10654816
  • 财政年份:
    2020
  • 资助金额:
    $ 37.25万
  • 项目类别:
Toxicological Profiling of Engineered Nanomaterials (ENMs) in the MPS (RES)
MPS (RES) 中工程纳米材料 (ENM) 的毒理学分析
  • 批准号:
    9186735
  • 财政年份:
    2016
  • 资助金额:
    $ 37.25万
  • 项目类别:
Toxicological Profiling of Engineered Nanomaterials (ENMs) in the MPS (RES)
MPS (RES) 中工程纳米材料 (ENM) 的毒理学分析
  • 批准号:
    9341321
  • 财政年份:
    2016
  • 资助金额:
    $ 37.25万
  • 项目类别:
Toxicological Profiling of Engineered Nanomaterials (ENMs) in the MPS (RES)
MPS (RES) 中工程纳米材料 (ENM) 的毒理学分析
  • 批准号:
    9769728
  • 财政年份:
    2016
  • 资助金额:
    $ 37.25万
  • 项目类别:
Center for Nanobiology and Predictive Toxicology
纳米生物学和预测毒理学中心
  • 批准号:
    8393965
  • 财政年份:
    2010
  • 资助金额:
    $ 37.25万
  • 项目类别:
Center for Nanobiology and Predictive Toxicology
纳米生物学和预测毒理学中心
  • 批准号:
    8464703
  • 财政年份:
    2010
  • 资助金额:
    $ 37.25万
  • 项目类别:
Nanovalve Platform: Targeted, Controlled, Release of Anticancer Drugs
Nanovalve平台:靶向、可控、释放抗癌药物
  • 批准号:
    8206804
  • 财政年份:
    2010
  • 资助金额:
    $ 37.25万
  • 项目类别:

相似海外基金

Optimizing Health and Well-Being of Diverse Mothers with IDD and Their Infants During the Perinatal Period: A Virtual Advocate Tool for Data-Driven Supports
优化患有 IDD 的不同母亲及其婴儿在围产期的健康和福祉:用于数据驱动支持的虚拟倡导工具
  • 批准号:
    10760051
  • 财政年份:
    2023
  • 资助金额:
    $ 37.25万
  • 项目类别:
POSE: Phase II: Advocate Led Long-term Gameplan for Open OnDemand (ALL GOOD)
POSE:第二阶段:倡导者主导 Open OnDemand 的长期游戏计划(一切顺利)
  • 批准号:
    2303692
  • 财政年份:
    2023
  • 资助金额:
    $ 37.25万
  • 项目类别:
    Standard Grant
Capitalising on our differences: A gathering to better understand and advocate for Early Career Health Researchers in Canada
利用我们的差异:更好地理解和倡导加拿大早期职业健康研究人员的聚会
  • 批准号:
    468168
  • 财政年份:
    2022
  • 资助金额:
    $ 37.25万
  • 项目类别:
    Miscellaneous Programs
Addressing social adversity to improve outcomes among children undergoing liver transplant: the role for a health advocate on the transplant team
解决社会逆境以改善接受肝移植的儿童的预后:移植团队中健康倡导者的作用
  • 批准号:
    10427960
  • 财政年份:
    2022
  • 资助金额:
    $ 37.25万
  • 项目类别:
Evaluating an ACEs-Targeting Advocate Model of a Substance Use Prevention Program
评估药物使用预防计划的针对 ACE 的倡导者模型
  • 批准号:
    10577074
  • 财政年份:
    2022
  • 资助金额:
    $ 37.25万
  • 项目类别:
The Art of Creation: Using Art-Based Knowledge Translation to Promote and Advocate for a Healthy Start to Life
创造的艺术:利用基于艺术的知识转化来促进和倡导健康的生命开端
  • 批准号:
    486588
  • 财政年份:
    2022
  • 资助金额:
    $ 37.25万
  • 项目类别:
    Studentship Programs
When I am Old, I shall Wear Purple Nail Varnish: Utilising performance art to construct queer spaces that celebrate and advocate for ageing bodies
当我老了,我要涂紫色指甲油:利用行为艺术构建酷儿空间,庆祝和倡导衰老的身体
  • 批准号:
    2760091
  • 财政年份:
    2022
  • 资助金额:
    $ 37.25万
  • 项目类别:
    Studentship
Addressing social adversity to improve outcomes among children undergoing liver transplant: the role for a health advocate on the transplant team
解决社会逆境以改善接受肝移植的儿童的预后:移植团队中健康倡导者的作用
  • 批准号:
    10621188
  • 财政年份:
    2022
  • 资助金额:
    $ 37.25万
  • 项目类别:
Techquity by FAITH!: A cluster randomized controlled trial to assess the efficacy of a community-informed, cardiovascular health promotion mobile hlth intervention with digital health advocate support
Techquity by FAITH!:一项整群随机对照试验,旨在评估社区知情、心血管健康促进移动 hlth 干预措施在数字健康倡导者支持下的效果
  • 批准号:
    10891016
  • 财政年份:
    2021
  • 资助金额:
    $ 37.25万
  • 项目类别:
CMV responses in autoantibody positive subjects advocate antiviral treatments for prevention of T1D
自身抗体阳性受试者的 CMV 反应主张抗病毒治疗以预防 T1D
  • 批准号:
    10230365
  • 财政年份:
    2020
  • 资助金额:
    $ 37.25万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了